Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 10/20 | 0.62 |
| ▸ | ESR1 | P03372 | 2/20 | 0.62 |
| ▸ | IKZF2 | Q9UKS7 | 8/20 | 0.57 |
| ▸ | WIZ | O95785 | 1/20 | 0.49 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27308323 | 0.97 | CRBN (0.61) | CRBNESR1IKZF2WIZIKZF1 | |
| SCHEMBL24735305 | 0.97 | CRBN (0.60) | CRBNESR1IKZF2WIZIKZF1 | |
| SCHEMBL22600233 | 0.97 | CRBN (0.60) | CRBNESR1IKZF2WIZIKZF1 | |
| SCHEMBL27423839 | 0.97 | CRBN (0.60) | CRBNESR1IKZF2WIZIKZF1 | |
| SCHEMBL29841272 | 0.97 | CRBN (0.60) | CRBNESR1IKZF2WIZIKZF1 | |
| Hydrochloric Acid SCHEMBL30906238 | 0.96 | CRBN (0.60) | CRBNESR1IKZF2WIZIKZF1 | |
| Hydrochloric Acid SCHEMBL22581049 | 0.96 | CRBN (0.60) | CRBNESR1IKZF2WIZIKZF1 | |
| Hydrochloric Acid SCHEMBL22581144 | 0.96 | CRBN (0.60) | CRBNESR1IKZF2WIZIKZF1 | |
| Hydrochloric Acid SCHEMBL22581000 | 0.96 | CRBN (0.60) | CRBNESR1IKZF2WIZIKZF1 | |
| SCHEMBL31129737 | 0.96 | CRBN (0.58) | CRBNESR1IKZF2WIZIKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109716-A1 | CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO | ARVINAS OPERATIONS, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4655073-A2 | CEREBLON-BASED KRAS DEGRADING PROTACS ANS USES RELATED THERETO | Arvinas Operations, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12448399-B2 | Cereblon-based KRAS degrading PROTACs and uses related thereto | ARVINAS OPERATIONS, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| WO-2024159164-A2 | CEREBLON-BASED KRAS DEGRADING PROTACS ANS USES RELATED THERETO | ARVINAS OPERATIONS, INC. (US) | 2024-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448399-B2 | Cereblon-based KRAS degrading PROTACs and uses related thereto | CRBN, KRAS, WEE1 | CRBN 1/4885ESR1 1977/4885IKZF2 438/4885 |
| US-20260109716-A1 | CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO | KRAS, CRBN, HRAS | CRBN 2/4885ESR1 3094/4885IKZF2 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.